Select area to zoom
Created with Highcharts 11.1.0Apr '24Jul '24Oct '24Jan '2510.002.90

Profile

Edit
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
URL https://www.galmedpharma.com
Investor Relations URL http://galmedpharma.investorroom.com/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Jan. 14, 2025 (est.)
Last Earnings Release Aug. 28, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Edit
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
URL https://www.galmedpharma.com
Investor Relations URL http://galmedpharma.investorroom.com/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Jan. 14, 2025 (est.)
Last Earnings Release Aug. 28, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A
Quickflows